导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.18% | 3945/4773 |
| 近一周 | -3.37% | 3972/5458 |
| 近一月 | -2.88% | 1758/5421 |
| 近一季 | 1.28% | 693/5205 |
| 近半年 | -4.39% | 2666/4920 |
| 近一年 | -15.48% | 3740/4361 |
| 近两年 | 33.10% | 2202/2954 |
| 近三年 | 11.86% | 1709/2253 |
| 成立以来 | 37.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.99% 4689/4961 |
9.77% 2465/5312 |
- - |
- - |
| 2025 | 4.96% 3019/4813 |
-7.01% 3418/3635 |
4.88% 691/4076 |
11.87% 3119/4524 |
-3.79% 3341/4813 |
| 2024 | 28.71% 149/3463 |
-4.99% 1819/2808 |
-8.66% 2264/3014 |
42.94% 34/3129 |
3.77% 768/3463 |
| 2023 | 5.23% 195/2656 |
4.31% 987/2280 |
-2.61% 621/2385 |
8.08% 20/2515 |
-4.15% 893/2655 |
| 2022 | -25.80% 1346/2207 |
-18.61% 1359/1919 |
2.14% 1342/2016 |
-16.01% 1387/2113 |
6.27% 374/2208 |
| 2021 | 3.26% 620/1822 |
-13.63% 1159/1255 |
9.05% 588/1330 |
7.34% 190/1466 |
2.14% 687/1822 |
| 2020 | - - |
- - |
10.69% 758/1067 |
24.69% 26/1164 |
2.22% 1004/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |